Under the Radar Biotech Breakthrough in Metastasizing Cancer Testing

MetaStat, Inc. (OTCQB: MTST) MetaStat is a life sciences company that develops and commercializes diagnostic products and novel therapeutics for the early and reliable prediction and treatment of systemic metastasis, the process by which cancer spreads from a primary tumor through the bloodstream to other areas of the body. MetaStat is focused on breast, prostate, lung and colorectal cancers, where systemic metastasis is responsible for approximately 90% of all deaths. The company's function-based diagnostic platform technology is based on the identification and understanding of the pivotal role of the mena protein and its isoforms, a common pathway for the development of systemic metastatic disease in all epithelial-based solid tumors. Both the MetaSite Breast™ and MenaCalc™ product lines are designed to accurately stratify patients based on their individual risk of metastasis and to allow clinicians to better "customize" cancer treatment decisions by positively identifying patients with a high-risk of metastasis who need aggressive therapy and by sparing patients with a low-risk of metastasis from the harmful side effects and expense of chemotherapy. Additionally, the MenaBloc™ therapeutic program aims to build upon mena biology and alternative splicing events as a driver of disease progression to exploit novel targets that provide precision medicines in oncology.

MetaStat is developing two function-based diagnostic assays: i) the MetaSite Breast™ test for early stage breast cancer patients and ii) MenaCalc™, which MetaStat believes is broadly applicable in epithelial-based cancers, including breast, prostate, lung and colorectal. These four cancers collectively account for over 50% of all new cancer cases in the U.S. and according to the American Cancer Society statistics is a $2.4 billion annual market opportunity. Both MetaSite Breast™ and MenaCalc™ diagnostic products lines benefit from MetaStat’s proprietary understanding of the mechanics and genetics of the metastatic process and enable clinicians to accurately stratify patients based on their individual risk of metastasis.

MenaBloc™ is a therapeutic platform focusing on Mena biology by targeting alternative splicing events (ASE) that drive the epithelial-mesenchymal transition (EMT). MetaStat believes these novel ASE targets will provide a valuable treatment option to delay tumor progression and decrease metastatic spread. Further, in published proof-of-concept animal studies, the deficiency of Mena decreased metastasis and dramatically increased survival by (i) slowing tumor progression and (ii) reducing tumor cell invasion and intravasation.

MetaStat recently announced the completion of a clinical study that showed the MetaSite Breast™ test predicts metastasis. The sponsored study was conducted in collaboration with Albert Einstein College of Medicine of Yeshiva University and Weill Cornell Medical College. The recently completed study involving 481 women with breast cancer confirmed that the MetaSite Breast™ diagnostic was found to be associated with a statistically significant increase in the risk of distant metastasis.

Some of the other hot OTC stocks creating investor buzz this week are: Terra Tech Corp (OTCQB: TRTC) which engages in the design, manufacture, marketing, and sale of horticulture equipment for indoor agriculture. Fannie Mae (OTCQB: FNMA) Press wires have been abuzz lately about the possible action from the Senate Banking Committee to introduce a bill in the coming weeks that would bring overhaul to the mortgage financing industry. Fannie Mae also said in its annual report, "we are no longer managed with a strategy to maximize shareholder returns," and "every dollar of earnings that Fannie Mae and Freddie Mac generate will be used to benefit taxpayers for their investment in those firms." Alternative Energy Partners, Inc. (OTCQB: AEGY) doing business as PharmaJanes™, has an e-commerce medical marijuana order servicing platform at http://www.PharmaJanes.com, is fully operational. Patients have received their completed orders in the initial roll-out service areas in the San Fernando Valley in Los Angeles.

New technologies and the markets they occupy are the driving force of the OTC markets growth. Get a full CFA report with price target and analyst recommendation by visiting the following link: http://smallcapir.com/?p=747 copy and paste may be required

We are offering this amazing opportunity FREE to the first 500 followers.

Our members will get Pre-Promotion VIP Early Alerts from the most effective newsletters in the industry and the best part is they are delivered in real time via our PRIVATE TWITTER FEED: https://twitter.com/ALLVIPALERTS

No Credit Card No Spam No Obligation No Emails

This is a no brainer. We are paying thousands in VIP memberships to bring you the best picks in real time from the top newsletters in the industry. Join Now! Use the link above to become one the first followers to ALLVIPALERTS.

ProTek Capital (CE) (USOTC:PRPM)
Historical Stock Chart
From Mar 2024 to Apr 2024